HomeTrialNCT04783428
🔬NCT04783428ACTIVE NOT RECRUITING

Tumor-induced Osteomalacia Disease Monitoring Program

Study Summary

The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment23 participants
Primary Completion
Lead SponsorUltragenyx Pharmaceutical Inc
Data Retrieved2026-04-11 04:25:35.045584+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.